According to Galapagos NV's latest financial reports the company's current EPS (TTM) is -$2.59. In 2022 the company made an earnings per share (EPS) of -$3.59 a decrease over its 2021 EPS that were of -$1.87.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -$2.59 | -27.74% |
2022 | -$3.59 | 92.01% |
2021 | -$1.87 | -65.42% |
2020 | -$5.40 | -321.1% |
2019 | $2.44 | -444.23% |
2018 | -$0.71 | -73.64% |
2017 | -$2.69 | -312.87% |
2016 | $1.26 | -134.51% |
2015 | -$3.67 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $14.09 | -643.56% | ๐บ๐ธ USA |
Abbott Laboratories ABT | $2.97 | -214.70% | ๐บ๐ธ USA |
AbbVie ABBV | $3.68 | -242.04% | ๐บ๐ธ USA |
Sanofi SNY | $3.18 | -222.73% | ๐ซ๐ท France |
Merck MRK | $1.82 | -170.30% | ๐บ๐ธ USA |
AstraZeneca AZN | $1.98 | -176.60% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $3.50 | -235.10% | ๐ฌ๐ง UK |
Fortress Biotech
FBIO | -$10.79 | 316.39% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | -$2.00 | -22.82% | ๐ฎ๐ฑ Israel |